Treatment of drowsiness, improves memory and concentration.
Armodafinil refers to analeptics and eugeroics (eugeoics) – drugs that enhance wakefulness without excessive stimulation of the central nervous system (in contrast to amphetamines and their substituted derivatives).
Approved as a drug for enhancing wakefulness and reducing sleepiness in patients with obstructive sleep apnea, narcolepsy, as well as in people with sleep disorders due to night work (with the so-called “night shift syndrome”, the ICD code -10 G47.26)
Armodafinil is an (R) – (-) – enantiomer of modafinil. Modafinil is a mixture of two enantiomers: (R) – (-) – modafinil and (S) – (+) – modafinil, and sold under the name ARTVIGIL-150
Armodafinil is an enantiomerically pure form of wakefulness-promoting substance, or eugeroid. It consists only of the (-) – (R) -enantiomer of racemic modafinil. Armomafinil was approved by the US Food and Drug Administration (FDA) in June 2007.
Although both substances have similar half-lives, armodafinil reaches its peak in blood later than modafinil, which can make it more effective as a wake-up substance in patients with excessive daytime drowsiness.
Armofinil is currently approved by the FDA for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy and shift work. It is widely used not for its intended purpose for the treatment of attention deficit hyperactivity disorder, chronic fatigue syndrome, and major depressive disorder. It has been shown that it improves the vigilance of air traffic controllers.
Armofinil 150 mg is approved by the US FDA for the treatment of narcolepsy and sleep disorders associated with shift work, and as an adjuvant therapy for obstructive sleep apnea. For the treatment of narcolepsy and the syndrome of obstructive sleep apnea, Armodifinil is taken once a day at a dose of 150 mg or 250 mg in the morning. To treat a sleep disorder associated with shift work, Armomafinil is taken at a dose of 150 mg one hour before work commences. Dose titration is necessary to mitigate some of the side effects.
In June 2010, it was revealed that the study of armodifinil Phase II as an adjunctive therapy in adults with schizophrenia could not satisfy the primary endpoints, and the clinical program was subsequently discontinued. However, a study published in the same year showed that schizophrenia patients who received armomafinil had fewer negative symptoms of schizophrenia.
Dosage for medical diagnosis
In standard doses, recommended for a patient with narcolepsy is 150-250 mg per day. It should be noted that elderly patients and those with impaired liver function will require lower doses, but in some patients, taking Armodafinil to combat their narcolepsy find that they become anxious, irritable and nervous at low dose recommendations of 150 mg every day.
There is a small risk of a serious overdose of Armodafinil, but you should not use more than 250 mg in 24 hours to prevent side effects.
Another example: Prescribing instructions for patients with obstructive sleep apnea (OCA) is also 150-250 mg per day, However, the literature quickly adds that OSA patients showed no additional benefits by taking 250 mg instead of reducing the dose of 150 mg.